DropGenie Raises $5 Million in Seed+ Funding for Biology Platform Growth
Montreal-based biotechnology firm DropGenie has secured $5 million in Seed+ financing to expand its patient-derived cell testing capabilities.
DropGenie, a company specializing in functional biology, has closed a $5 million Seed+ financing round led by BDC Thrive. The capital is designated to increase the output of the company’s platform, which generates biological data for drug discovery processes.
By focusing on patient-derived cells, DropGenie aims to provide research teams with actionable insights that traditionally require complex, in-house laboratory setups. The platform is designed to provide on-demand testing, addressing bottlenecks in the preclinical research pipeline.
The influx of capital will support the company’s efforts to scale its data partnerships. DropGenie plans to use the resources to expand its technical capacity and support a broader range of discovery projects within the pharmaceutical industry.